Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms

Pediatric Blood & Cancer(2023)10.1002/pbc.30584Source: DataRank Database

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms is a research paper published in Pediatric Blood & Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 26 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access26 citations

Download PDF

Cite:

Linked data & code

refsnp nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 4.82)OA: bronzeTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Todd A. Alonzo ORCID,Sarah K. Tasian ORCID,Matthew A. Kutny ORCID,Johann Hitzler ORCID,Jessica A. Pollard ORCID

Live enrichment

PubMed:37480164 PMC:PMC10614720 OpenAlex:https://openalex.org/W4385064330

National Cancer Institute

Grant: U10CA098413

National Cancer Institute

Grant: U10CA098543

National Cancer Institute

Grant: U10CA180899

National Cancer Institute

Grant: U10CA180886

National Cancer Institute

Grant: U24CA196173

National Cancer Institute

Grant: UG1CA233249

National Institutes of Health

FWCI

4.82

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pbc.30584

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pbc.30584

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30584

journalhttps://doi.org/10.1002/pbc.30584

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37480164

Fields of Study

Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentHistone Deacetylase Inhibitors ResearchHumansChildLeukemia, Myeloid, AcutePrognosisSorafenibAntineoplastic AgentsGemtuzumabMutationfms-Like Tyrosine Kinase 3Hematopoietic Stem Cell Transplantation

MeSH Terms

SorafenibGemtuzumabAntineoplastic AgentsChildHumansMutationPrognosisLeukemia, Myeloid, AcuteHematopoietic Stem Cell Transplantationfms-Like Tyrosine Kinase 3

Keywords

MedicineGemtuzumab ozogamicinOncologyInternal medicineClinical trialSorafenibMyeloid leukemiaHematopoietic stem cell transplantationCD33DiseaseHematologyIntensive care medicineStem cellCD34AMlChemotherapyClinical TrialsMolecular Diagnosis And TherapySub-specialty Classification

Sustainable Development Goals

SDG 0: Good health and well-being